[Autoimmune hepatitis]

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

[Autoimmune hepatitis]

Verh Dtsch Ges Pathol. 1995;79:177-85. Unique Identifier : AIDSLINE MED/96170455
Dienes HP; Institut fur Pathologie des Universitatsklinikums Mainz.

Abstract: The morphology of autoimmune hepatitis is characterized by portal-periportal predilection of necroinflammatory lesions. In comparison to the viral type of hepatitis severe piece-meal-necroses, the collapse of periportal parenchyma, and to a higher degree acinar transformation of hepatocytes are more prominent. The autoimmune hepatitis may start with acute disease displaying unusual clinical und histopathologic features. The postinfantile giant cell hepatitis seems to constitute a variant of autoimmune hepatitis. Autoimmune hepatitis has been reproduced in animal models and it could be demonstrated in rabbits that humoral immunity plays a role in tissue damage. The importance of cellular mechanisms could be analyzed in syngenic mice showing that the CD4-positive lymphocytes play a pivotal role. The most promising candidate antigen seems to be the asialoglycoprotein-receptors including the liver specific protein (LSP). By immunohistologic analysis dense deposits of IgG could be demonstrated in sinusoids and on the membranes of hepatocytes. In accordance with in vitro data the determination of CD4 positive lymphocytes in the tissue was found to play a decisive role in cellular immune reaction. The HSP65 molecule seems to evoke mechanisms that have been shown to play a pathogenetic role in experimental arthritis.

Keywords: Animal Antibody Formation Autoimmune Diseases/*PATHOLOGY CD4-Positive T-Lymphocytes/IMMUNOLOGY/PATHOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY/PATHOLOGY English Abstract Hepatitis/*IMMUNOLOGY/PATHOLOGY Hepatitis, Animal/*IMMUNOLOGY/PATHOLOGY Human Immunity, Cellular Mice Models, Immunological Rabbits JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
960730
M9670487

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .